By: Courtney Flaherty From: onclive.com Patients with select rare breast cancer subtypes, such as metaplastic and lobular histologies, achieved high pathologic complete response (pCR) rates with response-predictive subtype (RPS)–optimized treatment with a checkpoint inhibitor, although patients with rare breast cancers overall experienced shorter event-free survival (EFS) vs those with no special type (NST), according to data from an analysis of …
I-SPY 2 Framework Could Represent the Future of Drug Development in Breast Cancer
By: Caroline Seymour From: onclive.com Traditional paradigms for clinical trials have limited accelerated progress in breast cancer treatment, leading investigators to place more emphasis on efficiencies in research. By moving away from adjuvant- to neoadjuvant-based protocols, such as I-SPY, investigators may be better able to develop effective treatments for patients in less time by refining the understanding of who will …
UCSF and I-SPY 2 Breast Cancer Researchers Develop Newly Redefined Breast Cancer Response Subtypes
Source Quantum Leap Healthcare Collaborative From: PR Newswire Improved Classifications May Increase Precision in Targeted Therapies Research scientists and statisticians from UC San Francisco have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients. The new cancer response subtypes reflect responsiveness to drug treatments and are intended to help …
UCSF-led clinical trial model may present a better way to test new breast cancer drugs
By Josh Baxt From: medcitynews.com Clinical trials have a long rap sheet: expensive, slow, inaccurate, prone to failure. Patients, researchers, and investors wait impatiently for that elusive signal to show up – often in vain. But now, a UC San Francisco-led group may be developing a better way. Their solution is a platform trial called I-SPY – which stands for Investigating …